Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis-Reference-Cited by-同舟云学术

Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis

Published:2022-02-28 Issue:2 Volume:17 Page:153-166
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Van Sanden Suzy^ORCID,Murton Molly,Bobrowska Anna,Rahhali Nora,Sermon Jan,Rodrigues Bernardo,Goff-Leggett Danielle,Chouaid Christos,Sebastian Martin,Greystoke Alastair

Funder

Janssen EMEA

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-022-00868-z.pdf

Reference43 articles.

1. Ferlay J, Colombet M, Soerjomataram I, Siegel R, Torre L, Jemal A. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. World Health Organization, International Agency for Research on Cancer: Lyon, France. 2018.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

3. Eurostat. Cancer statistics - specific cancers 2020. https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cancer_statistics_-_specific_cancers#Lung_cancer. Accessed 21 May 2021.

4. National Cancer Institute Surveillance Epidemiology and End Results Program. Percent distribution and counts by histology among histologically confirmed cases, 2013–2017 both sexes by race 2017. https://seer.cancer.gov/archive/csr/1975_2017/results_single/sect_15_table.28.pdf. Accessed 18 January 2022.

5. Zhu Q-G, Zhang S-M, Ding X-X, He B, Zhang H-Q. Driver genes in non-small cell lung cancer: characteristics, detection methods, and targeted therapies. Oncotarget. 2017;8(34):57680.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

2. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation;Targeted Oncology;2024-02-28

3. Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability;BMC Proceedings;2024-01-18

4. Rapid and reliable testing for clinically actionable EGFR mutations in non-small cell lung cancer using the Idylla ^TM platform: a real-world two-center experience in Greece;Expert Review of Molecular Diagnostics;2024-01-11

5. A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study;Cancer Treatment and Research Communications;2024